Abbott India Limited (ABBOTINDIA.BO)
INR 28764.0
(2.24%)
INR 28764.0
(2.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -20.51 Billion INR | -1521.55% |
| 2022 | -1.26 Billion INR | -766.49% |
| 2021 | 189.8 Million INR | 128.89% |
| 2020 | -656.9 Million INR | -320.81% |
| 2019 | 297.49 Million INR | 121.71% |
| 2018 | -1.37 Billion INR | -263.63% |
| 2017 | -376.77 Million INR | 81.37% |
| 2016 | -2.02 Billion INR | -44.26% |
| 2015 | -1.4 Billion INR | -186.12% |
| 2014 | -489.97 Million INR | 89.41% |
| 2013 | -4.62 Billion INR | -322.86% |
| 2012 | -1.09 Billion INR | 57.73% |
| 2011 | -2.58 Billion INR | -37.36% |
| 2010 | -1.88 Billion INR | -7.35% |
| 2009 | -1.75 Billion INR | -7.88% |
| 2008 | -1.62 Billion INR | -918.01% |
| 2007 | -159.9 Million INR | -35.85% |
| 2006 | -117.7 Million INR | -56.31% |
| 2005 | -75.3 Million INR | 27.03% |
| 2004 | -103.2 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 19.51 Billion INR | 501.07% |
| 2023 Q2 | -4.86 Billion INR | -125.31% |
| 2023 Q4 | -20.51 Billion INR | -205.11% |
| 2023 FY | -20.51 Billion INR | -1521.55% |
| 2023 Q1 | 19.22 Billion INR | 1619.68% |
| 2022 Q4 | -1.26 Billion INR | -107.1% |
| 2022 Q1 | 27.35 Billion INR | 14310.85% |
| 2022 Q2 | -1.64 Billion INR | -106.0% |
| 2022 FY | -1.26 Billion INR | -766.49% |
| 2022 Q3 | 17.82 Billion INR | 1186.11% |
| 2021 Q3 | 22.7 Billion INR | 2132.27% |
| 2021 FY | 189.8 Million INR | 128.89% |
| 2021 Q1 | 24 Billion INR | 3754.18% |
| 2021 Q4 | 189.8 Million INR | -99.16% |
| 2021 Q2 | 1.01 Billion INR | -95.76% |
| 2020 Q4 | -656.9 Million INR | -103.38% |
| 2020 Q1 | 21.97 Billion INR | 7286.2% |
| 2020 Q2 | -221.2 Million INR | -101.01% |
| 2020 Q3 | 19.42 Billion INR | 8880.47% |
| 2020 FY | -656.9 Million INR | -320.81% |
| 2019 Q3 | 18.13 Billion INR | 945.06% |
| 2019 Q2 | -2.14 Billion INR | -112.78% |
| 2019 Q1 | 16.79 Billion INR | 1325.55% |
| 2019 FY | 297.49 Million INR | 121.71% |
| 2019 Q4 | 297.49 Million INR | -98.36% |
| 2018 Q3 | 13.22 Billion INR | 1047.01% |
| 2018 FY | -1.37 Billion INR | -263.63% |
| 2018 Q4 | -1.37 Billion INR | -110.36% |
| 2018 Q2 | -1.39 Billion INR | -113.62% |
| 2018 Q1 | 10.25 Billion INR | 2820.56% |
| 2017 Q3 | 11.96 Billion INR | 1888.74% |
| 2017 Q2 | -669 Million INR | -106.17% |
| 2017 Q1 | 10.84 Billion INR | 636.42% |
| 2017 FY | -376.77 Million INR | 81.37% |
| 2017 Q4 | -376.77 Million INR | -103.15% |
| 2016 Q3 | 8.84 Billion INR | 509.36% |
| 2016 Q4 | -2.02 Billion INR | -122.86% |
| 2016 Q2 | -2.16 Billion INR | -125.74% |
| 2016 FY | -2.02 Billion INR | -44.26% |
| 2016 Q1 | 8.39 Billion INR | 698.77% |
| 2015 Q2 | -7.15 Billion INR | -211.19% |
| 2015 Q1 | 6.43 Billion INR | 1414.15% |
| 2015 Q4 | -1.4 Billion INR | -119.58% |
| 2015 Q3 | 7.15 Billion INR | 200.0% |
| 2015 FY | -1.4 Billion INR | -186.12% |
| 2014 Q1 | 4.62 Billion INR | 200.0% |
| 2014 FY | -489.97 Million INR | 89.41% |
| 2014 Q3 | 5.58 Billion INR | 200.0% |
| 2014 Q2 | -5.58 Billion INR | -220.77% |
| 2014 Q4 | -489.97 Million INR | -108.77% |
| 2013 Q4 | -4.62 Billion INR | 0.0% |
| 2013 FY | -4.62 Billion INR | -322.86% |
| 2013 Q2 | 3.85 Billion INR | 200.0% |
| 2013 Q1 | -3.85 Billion INR | -4.71% |
| 2012 Q4 | -3.68 Billion INR | -236.27% |
| 2012 FY | -1.09 Billion INR | 57.73% |
| 2012 Q3 | -1.09 Billion INR | 0.0% |
| 2011 FY | -2.58 Billion INR | -37.36% |
| 2011 Q3 | -2.58 Billion INR | 0.0% |
| 2010 FY | -1.88 Billion INR | -7.35% |
| 2009 FY | -1.75 Billion INR | -7.88% |
| 2008 FY | -1.62 Billion INR | -918.01% |
| 2007 FY | -159.9 Million INR | -35.85% |
| 2006 FY | -117.7 Million INR | -56.31% |
| 2005 FY | -75.3 Million INR | 27.03% |
| 2004 FY | -103.2 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Cipla Limited | -3.15 Billion INR | -550.038% |
| Gland Pharma Limited | -14.67 Billion INR | -39.802% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -2942.916% |
| Kopran Limited | 850.3 Million INR | 2512.39% |
| Marksans Pharma Limited | -4.29 Billion INR | -377.575% |
| NGL Fine-Chem Limited | 307.22 Million INR | 6776.757% |
| Pfizer Limited | -19.52 Billion INR | -5.076% |
| Sanofi India Limited | -3.87 Billion INR | -429.357% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 938.728% |